Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Williams-Sonoma, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Williams-Sonoma, Inc. trades at $250.52 (market cap $29.51B). The key difference: Alnylam Pharmaceuticals, Inc. and Williams-Sonoma, Inc. are close in size by market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WSM | |
|---|---|---|
Market Cap | $29.60B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $251.81 |
52-Week Low | $205.48 | $168.64 |
Enterprise Value | $27.56B | $30.35B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Williams-Sonoma (WSM) trades at $245.16, down 2.26% today, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Recent news highlights investor interest and a CEO stock sale, while cash flow trends show variability, with 2025 net cash flow at -$49 million.
Outlook remains positive with consistent earnings performance and a 'Moderate Buy' analyst consensus, though risks include consumer discretionary sector volatility and competitive pressures. The stock trades above the consensus price target of $231.10, suggesting limited near-term upside based on current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
